{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:05:25Z","timestamp":1781625925057,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T00:00:00Z","timestamp":1765152000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Ulm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) are a transformative therapy for many cancers, including head and neck cancer (HNC). However, their unique mechanism can trigger immune-related adverse events. Rare but significant are immune-related neuromuscular complications, impacting quality of life and prognosis. Using the TriNetX Global Health Research Network, 17,112 HNC patients treated with ICIs were analyzed for neuromuscular complications (inflammatory myopathies, myocarditis, myasthenia gravis, and neuropathies) identified via ICD-10 codes. Frequencies, timing, and survival probabilities were compared between patients with and without complications. The vast majority of the cohort received anti-PD-1 therapy. Neuromuscular complications occurred in 2.09% of patients (355\/17,112), with 437 total diagnoses indicating multiple complications per patient. Inflammatory myopathies were most common (54.23%), followed by myocarditis (27.92%), neuropathy (9.38%), and myasthenia gravis (8.47%). Patients with Myasthenia gravis complications were older (76 vs. 69 years), while neuropathy was more frequent in men, and inflammatory myopathies skewed toward women. Complications typically emerged within the first few months of treatment, though inflammatory myopathies also developed after 12 months. Survival analysis showed no significant difference between patients with and without complications, except for myocarditis, which was associated with worse survival. With our very large cohort of patients treated with immune checkpoint inhibitors (ICIs), we can demonstrate that neuromuscular complications of ICI therapy are rare but clinically significant. Cardiac involvement, particularly myocarditis, carries the worst prognosis. Prompt recognition and multidisciplinary management by oncologists and neurologists are essential to optimize outcomes in affected patients.<\/jats:p>","DOI":"10.1038\/s41598-025-31483-3","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T18:17:40Z","timestamp":1764958660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Incidence and outcomes of neuromuscular immune-related adverse events in head and neck cancer patients treated with checkpoint inhibitors"],"prefix":"10.1038","volume":"15","author":[{"given":"Stefanie","family":"Glaubitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Zsch\u00fcntzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Sakkas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Scheurer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Wilde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Schramm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Ebeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,5]]},"reference":[{"key":"31483_CR1","doi-asserted-by":"publisher","first-page":"705614","DOI":"10.3389\/fonc.2021.705614","volume":"11","author":"R. W. Hsieh","year":"2021","unstructured":"Hsieh, R. W., Borson, S., Tsagianni, A. & Zandberg, D. P. Immunotherapy in Recurrent\/Metastatic Squamous Cell Carcinoma of the Head and Neck. Front. Oncol. 11, 705614. (2021). https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.705614\/full","journal-title":"Front. Oncol."},{"issue":"9","key":"31483_CR2","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.3390\/cancers12092691","volume":"12","author":"C. Borel","year":"2020","unstructured":"Borel, C., Jung, A. C. & Burgy, M. Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma. Cancers 12 (9), 2691 (2020). https:\/\/www.mdpi.com\/2072-6694\/12\/9\/2691","journal-title":"Cancers"},{"issue":"5","key":"31483_CR3","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.3390\/curroncol29050247","volume":"29","author":"Y. Shiravand","year":"2022","unstructured":"Shiravand, Y. et al. Immune Checkpoint Inhibitors in Cancer Therapy. Curr. Oncol. 29 (5), 3044\u20133060 (2022). https:\/\/www.mdpi.com\/1718-7729\/29\/5\/247","journal-title":"Curr. Oncol."},{"key":"31483_CR4","doi-asserted-by":"crossref","unstructured":"Postow, M. A., Sidlow, R. & Hellmann, M. D. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. Longo DL, editor. N Engl J Med. 378(2), 158\u201368. (2018). http:\/\/www.nejm.org\/doi\/10.1056\/NEJMra1703481","DOI":"10.1056\/NEJMra1703481"},{"issue":"9","key":"31483_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","volume":"16","author":"F. Martins","year":"2019","unstructured":"Martins, F. et al. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. Nat. Rev. Clin. Oncol. 16 (9), 563\u2013580 (2019). https:\/\/www.nature.com\/articles\/s41571-019-0218-0","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"31483_CR6","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","volume":"87","author":"D. Dubey","year":"2020","unstructured":"Dubey, D. et al. Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. Ann. Neurol. 87 (5), 659\u2013669. (2020). https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.25708","journal-title":"Ann. Neurol."},{"issue":"3","key":"31483_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1097\/NRL.0000000000000230","volume":"24","author":"M. Xu","year":"2019","unstructured":"Xu, M., Nie, Y., Yang, Y., Lu, Md, Y. T. & Su, Q. Risk of Neurological Toxicities Following the Use of Different Immune Checkpoint Inhibitor Regimens in Solid Tumors: A Systematic Review and Meta-analysis. Neurologist 24 (3), 75\u201383 (2019). https:\/\/journals.lww.com\/00127893-201905000-00001","journal-title":"Neurologist"},{"issue":"1","key":"31483_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11910-018-0810-1","volume":"18","author":"C. De Astaras","year":"2018","unstructured":"Astaras, C., De Micheli, R., Moura, B., Hundsberger, T. & Hottinger, A. F. Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management. Curr. Neurol. Neurosci. Rep. 18 (1), 3 (2018). http:\/\/link.springer.com\/10.1007\/s11910-018-0810-1","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"31483_CR9","doi-asserted-by":"crossref","unstructured":"Gul, R. et al. Immune Checkpoint Inhibitor-Associated Myocarditis: A Literature Review. Cureus [Internet]. 2024 Jan 25 [cited 2025 Feb 25]; Available from: https:\/\/www.cureus.com\/articles\/169834-immune-checkpoint-inhibitor-associated-myocarditis-a-literature-review","DOI":"10.7759\/cureus.52952"},{"issue":"9","key":"31483_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s11940-020-00635-3","volume":"22","author":"R. Garcia-Santibanez","year":"2020","unstructured":"Garcia-Santibanez, R., Khoury, M. & Harrison, T. B. Immune-Related Neuromuscular Complications of Checkpoint Inhibitors. Curr. Treat. Options Neurol. 22 (9), 27 (2020). https:\/\/link.springer.com\/10.1007\/s11940-020-00635-3","journal-title":"Curr. Treat. Options Neurol."},{"issue":"2","key":"31483_CR11","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1111\/1759-7714.13266","volume":"11","author":"J. Shi","year":"2020","unstructured":"Shi, J. et al. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related adverse reactions in the nervous system. Thorac. Cancer. 11 (2), 481\u2013487 (2020). https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1759-7714.13266","journal-title":"Thorac. Cancer"},{"issue":"2","key":"31483_CR12","doi-asserted-by":"publisher","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","volume":"6","author":"M. B. Palchuk","year":"2023","unstructured":"Palchuk, M. B. et al. A global federated real-world data and analytics platform for research. JAMIA Open. 6 (2), ooad035 (2023). https:\/\/academic.oup.com\/jamiaopen\/article\/doi\/10.1093\/jamiaopen\/ooad035\/7161780","journal-title":"JAMIA Open."},{"issue":"1","key":"31483_CR13","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1186\/s12885-022-09583-4","volume":"22","author":"M. Hertel","year":"2022","unstructured":"Hertel, M. et al. Comparison of five-year survival rates among patients with oral squamous cell carcinoma with and without association with syphilis: a retrospective case-control study. BMC Cancer. 22 (1), 454 (2022). https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09583-4","journal-title":"BMC Cancer"},{"key":"31483_CR14","doi-asserted-by":"publisher","first-page":"1080492","DOI":"10.3389\/fonc.2022.1080492","volume":"12","author":"M. Heym","year":"2023","unstructured":"Heym, M. et al. The risk of oral squamous cell carcinoma in patients with and without somatoform disorders including bruxism: A retrospective evaluation of 309,278 individuals. Front. Oncol. 12, 1080492 (2023). https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.1080492\/full","journal-title":"Front. Oncol."},{"issue":"6","key":"31483_CR15","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1007\/s00415-023-11625-1","volume":"270","author":"S. Rossi","year":"2023","unstructured":"Rossi, S. et al. Peripheral nervous system adverse events associated with immune checkpoint inhibitors. J. Neurol. 270 (6), 2975\u20132986 (2023). https:\/\/link.springer.com\/10.1007\/s00415-023-11625-1","journal-title":"J. Neurol."},{"key":"31483_CR16","doi-asserted-by":"publisher","first-page":"117955492110562","DOI":"10.1177\/11795549211056261","volume":"15","author":"K. Cheng","year":"2021","unstructured":"Cheng, K. et al. Neurological Adverse Events Induced by Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: Current Perspectives and New Development. Clin. Med. Insights Oncol. 15, 11795549211056261 (2021). https:\/\/journals.sagepub.com\/doi\/10.1177\/11795549211056261","journal-title":"Clin. Med. Insights Oncol."},{"issue":"16","key":"31483_CR17","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1212\/WNL.0000000000011795","volume":"96","author":"A. Marini","year":"2021","unstructured":"Marini, A. et al. Neurologic Adverse Events of Immune Checkpoint Inhibitors: A Systematic Review. Neurology 96 (16), 754\u2013766 (2021). https:\/\/www.neurology.org\/doi\/10.1212\/WNL.0000000000011795","journal-title":"Neurology"},{"key":"31483_CR18","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","volume":"106","author":"A. Moreira","year":"2019","unstructured":"Moreira, A. et al. Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors. Eur. J. Cancer. 106, 12\u201323 (2019). https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918314035","journal-title":"Eur. J. Cancer"},{"issue":"10","key":"31483_CR19","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s11910-018-0878-7","volume":"18","author":"J. C. Kao","year":"2018","unstructured":"Kao, J. C., Brickshawana, A. & Liewluck, T. Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors. Curr. Neurol. Neurosci. Rep. 18 (10), 63 (2018). http:\/\/link.springer.com\/10.1007\/s11910-018-0878-7","journal-title":"Curr. Neurol. Neurosci. Rep."},{"issue":"6","key":"31483_CR20","doi-asserted-by":"publisher","first-page":"e200314","DOI":"10.1212\/NXI.0000000000200314","volume":"11","author":"S. Rossi","year":"2024","unstructured":"Rossi, S. et al. Clinical Course of Neurologic Adverse Events Associated With Immune Checkpoint Inhibitors: Focus on Chronic Toxicities. Neurol. Neuroimmunol. Neuroinflamm. 11 (6), e200314 (2024). https:\/\/www.neurology.org\/doi\/10.1212\/NXI.0000000000200314","journal-title":"Neurol. Neuroimmunol. Neuroinflamm"},{"issue":"1","key":"31483_CR21","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","volume":"7","author":"D. B. Johnson","year":"2019","unstructured":"Johnson, D. B. et al. Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study. J. Immunotherapy Cancer. 7 (1), 134 (2019). https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0617-x","journal-title":"J. Immunotherapy Cancer"},{"issue":"24","key":"31483_CR22","doi-asserted-by":"publisher","first-page":"7737","DOI":"10.3390\/jcm12247737","volume":"12","author":"F. Frascaro","year":"2023","unstructured":"Frascaro, F. et al. Immune Checkpoint Inhibitors-Associated Myocarditis: Diagnosis, Treatment and Current Status on Rechallenge. JCM 12 (24), 7737 (2023). (2077). https:\/\/www.mdpi.com\/2077-0383\/12\/24\/7737","journal-title":"JCM"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31483-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31483-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:05:00Z","timestamp":1781622300000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-31483-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["31483"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-31483-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"29 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"43261"}}